8 completed, 5 active not recruiting, 3 terminated, 3 unknown. 9 Not applicable, 8 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow BRCA2 Gene Mutation: new trials by email Literature Review of BRCA2 Gene Mutation trials Research Report on BRCA2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Recruiting | University Medical Center Nijmegen | 3000 | 2020-03-01 | 2026-04-06 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of California, Davis | 11 | 2020-02-25 | 2026-05-14 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations Informational Intervention, Survey Administration - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 58 | 2018-04-05 | 2026-02-10 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Laboratory Biomarker Analysis, Pembrolizumab - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 21 | 2018-03-08 | 2026-04-03 |
| Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Durvalumab, Laboratory Biomarker Analysis, Olaparib - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2017-06-29 | 2024-11-19 |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis - BARD1 Gene Mutation, BRCA1 Gene Mutation | Not applicable | Suspended | M.D. Anderson Cancer Center | 5200 | 2017-04-18 | 2026-08-26 |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - ATM Gene Mutation, ATR Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 51 | 2017-03-03 | 2021-06-23 |
| Pancreatic Cancer Screening of High-Risk Individuals in Arkansas Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2 - Pancreatic Neoplasms, Peutz-Jegher's Syndrome | Not applicable | Withdrawn | University of Arkansas | 2015-11-01 | 2019-07-29 | |
| The Link Between BRCA Mutation and Endothelial Function Endothelial function assessment, Cardiovascular biomarkers, Endothelial cells - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Unknown | Rabin Medical Center | 82 | 2015-02-01 | 2017-07-18 |
| Cancer Prevention in Women With a BRCA Mutation Follow-up Telephone Genetic Counselling - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Unknown | Women's College Hospital | 300 | 2015-01-01 | 2016-06-09 |
| Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers Salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Active not recruiting | University Medical Center Nijmegen | 510 | 2015-01-01 | 2024-12-05 |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Advanced Malignant Neoplasm, ATM Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 150 | 2014-12-22 | 2026-06-12 |
| A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers DIM-Avail 100mg - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Not applicable | Completed | Rabin Medical Center | 23 | 2014-11-11 | 2020-11-12 |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis - Body Mass Index 25 or Greater, BRCA1 Gene Mutation | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 337 | 2014-09-17 | 2026-09-16 |
| Prospective Research of Outcomes After Salpingo-oophorectomy BRCA1 Gene Mutation, BRCA2 Gene Mutation | Completed | University of California, San Francisco | 100 | 2014-07-01 | 2022-09-07 | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients niraparib, Physician's choice - Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Terminated | Tesaro, Inc. | 216 | 2014-02-25 | 2022-11-15 |
Showing 20 of 23. Sign in to see all of them.
Ovarian Neoplasms (9) · Breast Neoplasms (7) · Fallopian Tube Neoplasms (3) · Colorectal Neoplasms, Hereditary Nonpolyposis (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Ataxia Telangiectasia (1) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Fatigue (1) · Hereditary pancreatitis (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Melanoma, Cutaneous Malignant (1) · Overweight (1) · Pancreatic Neoplasms (1)
Neoplasms by Site (15) · Neoplasms (14) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Genital Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Adnexal Diseases (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases, Female (9) · Genital Neoplasms, Female (9) · Gonadal Disorders (9) · Ovarian Diseases (9) · Skin Diseases (9)
niraparib (3) · Docetaxel (2) · olaparib (2) · rucaparib (2) · talazoparib (2) · 3,3'-diindolylmethane (1) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Carboplatin (1) · Curcumin (1) · Diet Therapy (1) · Disulfides (1) · Drug Therapy (1) · Early Intervention, Educational (1) · Educational Status (1)
M.D. Anderson Cancer Center (4) · Ohio State University Comprehensive Cancer Center (3) · Rabin Medical Center (2) · University Medical Center Nijmegen (2) · Hadassah Medical Organization (1) · Qian Qin (1) · Roswell Park Cancer Institute (1) · Rutgers, The State University of New Jersey (1) · SWOG Cancer Research Network (1) · Steven J Isakoff, MD, PhD (1) · Tesaro, Inc. (1) · University of Arkansas (1) · University of California, Davis (1) · University of California, San Francisco (1) · University of Washington (1)
United States (17) · Canada (4) · Israel (4) · Netherlands (3) · Belgium (2) · Italy (2) · Poland (2) · Spain (2) · Australia (1) · Austria (1) · Brazil (1) · France (1) · Germany (1) · Greece (1) · Hungary (1)
David Margel, MD, PhD (2) · Asher Y Salmon, MD, PhD (1) · Elizabeth M. Swisher, MD, PhD (1) · Emese Zsiros (1) · Eugenia Girda, MD (1) · Floor Backes, MD (1) · Heather H. Cheng (1) · Joanne A de Hullu, MD, PhD (1) · Joanne A. de Hullu, MD, PhD (1) · Karen H. Lu, MD, PhD (1) · Karen M Basen-Engquist (1) · Kelly Metcalfe, Dr. (1) · Kent D McKelvey, MD (1) · Leigha Senter, LGC (1)
PMID 26286255, PMID 31266460, PMID 34081085, PMID 34417675, PMID 34997316, PMID 36155347, PMID 36710203, PMID 36946440, PMID 37045546, PMID 37290104, PMID 37707822, PMID 39509704, PMID 41730824
P30CA072720 (1), P30CA093373 (1), U10CA180888 (1)